Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Kao
Johnny
J
Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, United States. johnny.rao@mountsinai.org
Ko
Eric C
EC
Eisenstein
Samuel
S
Sikora
Andrew G
AG
Fu
Shibo
S
Chen
Shu-Hsia
SH
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D039481:CD11b Antigen / Q000378:metabolism; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology* / Q000528:radiation effects; D007167:Immunotherapy; D007211:Indoles / Q000494:pharmacology; D022423:Myeloid Cells / Q000187:drug effects / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000473:pathology; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000494:pharmacology; D000077210:Sunitinib; D059016:Tumor Microenvironment / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D039481:CD11b Antigen; D007211:Indoles; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D019009:Proto-Oncogene Proteins c-kit; D000077210:Sunitinib